Systemic and autoimmune manifestations in myelodysplastic syndromes;Manifestations systémiques et auto-immunes des syndromes myélodysplasiques

Revue de Medecine Interne

Volumn 32, Issue 9, 2011, Pages 552-559

  Fain, O ^a   Braun, T ^a   Stirnemann, J ^a   Fenaux, P ^a  

^a UNIVERSITÉ PARIS 13   (France)

Author keywords

Myelodysplastic syndromes; Paraneoplastic syndromes; Polyarthritis; Relapsing polychondritis; Sweet's syndrome; Vasculitis

Indexed keywords

CORTICOSTEROID; IMMUNOSUPPRESSIVE AGENT;

ACUTE FEBRILE NEUTROPHILIC DERMATOSIS; BEHCET DISEASE; CLINICAL FEATURE; DISEASE ASSOCIATION; HUMAN; INFECTION COMPLICATION; MYELODYSPLASTIC SYNDROME; POLYARTHRITIS; REFRACTORY ANEMIA; RELAPSING POLYCHONDRITIS; SHORT SURVEY; SYSTEMIC VASCULITIS;

AUTOIMMUNE DISEASES; HUMANS; MYELODYSPLASTIC SYNDROMES;

EID: 80052265444     PISSN: 02488663     EISSN: 17683122     Source Type: Journal    
DOI: 10.1016/j.revmed.2010.08.005     Document Type: Short Survey

References (78)

1. Anderson L.A., Pfeiffer R.M., Landgren O., Gadalla S., Berndt S.I., Engels E.A. Risks of myeloid malignancies in patients with auto-immune conditions. Br J Cancer 2009, 100:822-828.
2. Reinhold-Keller E., Beuge N., Latza U., de Groot K., Rudert H., Nolle B., et al. An interdisciplinary approach to the care of patients with Wegener's granulomatosis: long-term outcome in 155 patients. Arthritis Rheum 2000, 43:1021-1032.
3. McCarthy C.J. Cytogenetic abnormalities and therapy-related myelodysplastic syndromes in rheumatic disease. Arthritis Rheum 1998, 41:1493-1496.
4. Knipp S., Hildebrandt B., Richter J., Haas R., Germing U., Gattermann N. Secondary myelodysplastic syndromes following treatment with azathioprine are associated with aberrations of chromosome 7. Haematologica 2005, 90:691-693.
5. Kwong Y.L. Azathioprine: association with therapy-related myelodysplastic syndrome and acute myeloid leukemia. J Rheumatol 2010, 37:485-490.
6. Saif M.W., Hopkins J.L., Gore S.D. Auto-immune phenomena in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia. Leuk Lymphoma 2002, 43:2083-2092.
7. Novaretti M.C., Sopelete C.R., Velloso E.R., Rosa M.F., Dorlhiac-Llacer P.E., Chamone D.A. Immunohematological findings in myelodysplastic syndrome. Acta Haematol 2001, 105:1-6.
8. Berthier S., Magy N., Gil H., Schneider M.B., Vuitton D.A., Dupond J.L. Myélodysplasies et maladies systémiques: une association non fortuite. Rev Med Interne 2001, 22:428-432.
9. Castro M., Conn D.L., Su W.P., Garton J.P. Rheumatic manifestations in myelodysplastic syndromes. J Rheumatol 1991, 18:721-727.
10. Okamoto T. Immunological abnormalities in myelodysplastic syndromes. Ryoikibetsu Shokogun Shirizu 1998, 22:213-216.
11. Enright H., Jacob H.S., Vercellotti G., Howe R., Belzer M., Miller W. Paraneoplastic auto-immune phenomena in patients with myelodysplastic syndromes: response to immunosuppressive therapy. Br J Haematol 1995, 91:403-408.
12. Hamidou M.A., Derenne S., Audrain M.A., Berthelot J.M., Boumalassa A., Grolleau J.Y. Prevalence of rheumatic manifestations and antineutrophil cytoplasmic antibodies in haematological malignancies. A prospective study. Rheumatology 2000, 39:417-420.
13. Bouali F., Berrah A., Si Ahmed-Bouali D., Harrieche F., Benhalima M., Hamladji R.M., et al. Manifestations immunes associées aux syndromes myélodysplasiques. Étude prospective de 40 patients. Rev Med Interne 2005, 26:777-783.
14. Roy-Peaud F., Paccalin M., Le Moal G., Landron C., Juhel L., Roblot P., et al. Association maladies systémiques et syndromes myélodysplasiques. Étude rétrospective portant sur 14 observations. Presse Med 2003, 32:538-543.
15. Giannouli S., Tzoanopoulos D., Ritis K., Kartalis G., Moutsopoulos H.M., Voulgarelis M. Auto-immune manifestations in human myelodysplasia: a positive correlation with interferon regulatory factor-1 (IRF-1) expression. Ann Rheum Dis 2004, 63:578-582.
16. Fain O., Guillevin L., Kaplan G., Sicard D., Lemaire V., Godeau P., et al. Vascularite et cancer: 14 cas. Ann Med Interne 1991, 142:486-504.
17. Hamidou M.A., Boumalassa A., Larroche C., Elkourri D., Bletry O., Grolleau J.Y. Systemic medium-size vessel vasculitis associated with chronic myelomonocytic leukaemia. Semin Arthritis Rheum 2001, 31:119-126.
18. Aslangul-Castier E., Papo T., Amoura Z., Baud O., Leblond V., Charlotte F., et al. Systemic vasculitis with bilateral perirenal haemorrhage in chronic myelomonocytic leukaemia. Ann Rheum Dis 2000, 59:390-393.
19. Fain O., Paries J., Hamidou M., Cacoub P., Godeau B., Stirnemann J., et al. Vasculitides and cancers: 60 cases. Arthritis Rheum 2004, 50:S436.
20. Yiannias J.A., el-Azhary R.A., Gibson L.E. Erythema elevatum diutinum: a clinical and histopathologic study of 13 patients. J Am Acad Dermatol 1992, 26:38-44.
21. Aractingi S., Bachmeyer C., Dombret H., Vignon-Pennamen D., Degos L., Dubertret L. Simultaneous occurrence of two rare cutaneous markers of poor prognosis in myelodysplastic syndrome: erythema elevatum diutinum and specific lesions. Br J Dermatol 1994, 131:112-117.
22. Hebbar M., Brouillard M., Wattel E., Decoulx M., Hatron P.Y., Devulder B., et al. Association of myelodysplastic syndrome and relapsing polychondritis: further evidence. Leukemia 1995, 9:731-733.
23. Michet C.J., McKenna C.H., Luthra H.S., O'Fallon W.M. Relapsing polychondritis. Survival and predictive role of early disease manifestations. Ann Intern Med 1986, 104:74-78.
24. Piette J.C., Papo T., Chavanon P., Huong D.L., Frances C., Godeau P. Myelodysplasia and relapsing polychondritis. J Rheumatol 1995, 22:1208-1209.
25. Francès C., el Rassi R., Laporte J.L., Rybojad M., Papo T., Piette J.C. Dermatologic manifestations of relapsing polychondritis. A study of 200 cases at a single center. Medicine 2001, 80:173-179.
26. Cohen P.R., Kurzrock R. Sweet's syndrome and malignancy. Am J Med 1987, 82:1220-1226.
27. Soppi E., Nousiainen T., Seppa A., Lahtinen R. Acute febrile neutrophilic dermatosis (Sweet's syndrome) in association with myelodysplastic syndromes: a report of three cases and a review of the literature. Br J Haematol 1989, 73:43-47.
28. Megarbane B., Bodemer C., Valensi F., Radford-Weiss I., Fraitag S., MacIntyre E., et al. Association of acute neutrophilic dermatosis and myelodysplastic syndrome with (6;9) chromosome translocation: a case report and review of the literature. Br J Dermatol 2000, 143:1322-1324.
29. Vignon-Pennamen M.D., Juillard C., Rybojad M., Wallach D., Daniel M.T., Morel P., et al. Chronic recurrent lymphocytic Sweet syndrome as a predictive marker of myelodysplasia: a report of 9 cases. Arch Dermatol 2006, 142:1170-1176.
30. Paydas S., Sahin B., Seyrek E., Soylu M., Gonlusen G., Acar A., et al. Sweet's syndrome associated with G-CSF. Br J Haematol 1993, 85:191-192.
31. Fukutoku M., Shimizu S., Ogawa Y., Takeshita S., Masaki Y., Arai T., et al. Sweet's syndrome during therapy with granulocyte colony-stimulating factor in a patient with aplastic anaemia. Br J Haematol 1994, 86:645-648.
32. Reuss-Borst M.A., Pawelec G., Saal J.G., Horny H.P., Muller C.A., Waller H.D. Sweet's syndrome associated with myelodysplasia: possible role of cytokines in the pathogenesis of the disease. Br J Haematol 1993, 84:356-358.
33. Yamauchi T., Ishida K., Iwashima Y., Ikegaya S., Kawai Y., Wakahara M., et al. Successful treatment of pyoderma gangrenosum that developed in a patient with myelodysplastic syndrome. J Infect Chemother 2003, 9:268-271.
34. George S.W., Newman E.D. Seronegative inflammatory arthritis in the myelodysplastic syndromes. Semin Arthritis Rheum 1992, 21:345-354.
35. Pajus I., Amor B. Manifestations rhumatologiques associées aux syndromes myélodysplasiques et myéloprolifératifs. Rev Rhum Mal Osteoartic 1992, 59:11-16.
36. Kohli M., Bennett R.M. An association of polymyalgia rheumatica with myelodysplastic syndromes. J Rheumatol 1994, 21:1357-13359.
37. Espinosa G., Font J., Munoz-Rodriguez F.J., Cervera R., Ingelmo M. Myelodysplastic and myeloproliferative syndromes associated with giant cell arteritis and polymyalgia rheumatica: a coincidental coexistence or a causal relationship?. Clin Rheumatol 2002, 21:309-313.
38. Kuzmich P.V., Ecker G.A., Karsh J. Rheumatic manifestations in patients with myelodysplastic and myeloproliferative diseases. J Rheumatol 1994, 21:1649-1654.
39. Hubscher O., Vilches A., Solmesky S., Riveros D. Polymyalgia rheumatica in patients with myelodysplastic syndromes. J Rheumatol 1996, 23:792-793.
40. Mok C.C., Lau C.S., Kumana C.R. Polymyalgia rheumatica as the rheumatological manifestation of myelodysplastic syndrome in a Chinese patient. Br J Rheumatol 1996, 35:496-497.
41. Billstrom R., Johansson H., Johansson B., Mitelman F. Immune-mediated complications in patients with myelodysplastic syndromes: clinical and cytogenetic features. Eur J Haematol 1995, 55:42-48.
42. Bensaid P., Vaillant L., Machet L., De Muret A., Roquejoffre P., Lorette G. Maladie de Horton et syndrome myélodysplasique associés à des manifestations cutanées inhabituelles. Ann Dermatol Venereol 1992, 119:217-220.
43. Berthelot J.M., Hamidou M., Dauty M., Rodet D., Maugars Y., Prost A. Joint manifestations in myelodysplastic syndromes. A report of three cases presenting as polymyalgia rheumatica. Rev Rhum Engl Ed 1997, 64:95-100.
44. Rizos E., Dimos G., Milionis H.J., Elisaf M.S. Temporal arteritis masquerading as chronic myelomonocytic leukemia. Clin Exp Rheumatol 2003, 21:685-686.
45. Kalra L., Delamere J.P. Lymphoreticular malignancy and monoclonal gammopathy presenting as polymyalgia rheumatica. Br J Rheumatol 1987, 26:458-459.
46. Merlet V. Prévalence du cancer chez 75 patients porteur d'une maladie de Horton et/ou une pseudopolyarthrite rhizomélique. Étude rétrospective de 1987 à 1997 en médecine interne. Clermont-Ferrand: Thèse de médecine; 1998.
47. Kimura S., Kuroda J., Akaogi T., Hayashi H., Kobayashi Y., Kondo M. Trisomy 8 involved in myelodysplastic syndromes as a risk factor for intestinal ulcers and thrombosis: Behçet's syndrome. Leuk Lymphoma 2001, 42:115-121.
48. Becker K., Fitzgerald O., Green A.J., Keogan M., Newbury-Ecob R., Greenhalgh L., et al. Constitutional trisomy 8 and Behçet syndrome. Am J Med Genet A 2009, 149A:982-986.
49. Kuttikat A., Haskard D., Chakravarty K. Behçet's disease associated with trisomy 8 in a male Caucasian patient from Great Britain: a case report. Clin Exp Rheumatol 2005, 23(4 Suppl. 38):S108-S109.
50. Thachil J.V., Salim R., Field A., Moots R., Bolton-Maggs P. Myelodysplastic syndrome with trisomy 8 associated with Behçet syndrome: an immunologic link to a karyotypic abnormality. Pediatr Blood Cancer 2008, 50:649-651.
51. Tomonari A., Tojo A., Takahashi T., Iseki T., Ooi J., Takahashi S., et al. Resolution of Behcet's disease after HLA-mismatched unrelated cord blood transplantation for myelodysplastic syndrome. Ann Hematol 2004, 83:464-466.
52. Morschhauser F., Wattel E., Pagniez D., Lovi V., Rose C., Bauters F., et al. Glomerular injury in chronic myelomonocytic leukemia. Leuk Lymphoma 1995, 18:479-483.
53. Saitoh T., Murakami H., Uchiumi H., Moridaira K., Maehara T., Matsushima T., et al. Myelodysplastic syndromes with nephrotic syndrome. Am J Hematol 1999, 60:200-204.
54. Eng C., Farraye F.A., Shulman L.N., Peppercorn M.A., Krauss C.M., Connors J.M., et al. The association between the myelodysplastic syndromes and Crohn disease. Ann Intern Med 1992, 117:661-662.
55. Xue Y., Han Y., Li T., Chen S., Zhang J., Pan J., et al. Pulmonary alveolar proteinosis as a terminal complication in a case of myelodysplastic syndrome with idic(20q-). Acta Haematol 2010, 123:55-58.
56. Trapnell B.C., Carey B.C., Uchida K., Suzuki T. Pulmonary alveolar proteinosis, a primary immunodeficiency of impaired GM-CSF stimulation of macrophages. Curr Opin Immunol 2009, 21:514-521.
57. Ando J., Tamayose K., Sugimoto K., Oshimi K. Late appearance of t(1;19)(q11;q11) in myelodysplastic syndrome associated with dysplastic eosinophilia and pulmonary alveolar proteinosis. Cancer Genet Cytogenet 2002, 139:14-17.
58. Hamblin T.J. Immunological abnormalities in myelodysplastic syndromes. Semin Hematol 1996, 33:150-162.
59. Giagounidis A.A., Haase S., Germing U., Heinsch M., Aul C. Auto-immune disorders in two patients with myelodysplastic syndrome and 5q deletion. Acta Haematol 2005, 113:146-149.
60. Park S.J., Han C.W., Lee J.H., Eom H.S., Lee S.H., Jeong D.C., et al. Cyclosporine A in the treatment of a patient with immune thrombocytopenia accompanied by myelodysplastic syndrome and nephrotic syndrome. Acta Haematol 2003, 110:36-40.
61. Jimenez-Balderas F.J., Morales-Polanco M.R., Gutierrez L. Acute sideroblastic anemia in active systemic lupus erythematosus. Lupus 1994, 3:157-159.
62. Miescher P.A., Favre H., Beris P. Auto-immune myelodysplasias. Semin Hematol 1991, 28:322-330.
63. Lin J.T., Wang W.S., Yen C.C., Chiou T.J., Liu J.H., Hsiao L.T., et al. Myelodysplastic syndrome complicated by auto-immune hemolytic anemia: remission of refractory anemia following mycophenolate mofetil. Ann Hematol 2002, 81:723-726.
64. Baumann I., Scheid C., Koref M.S., Swindell R., Stern P., Testa N.G. Autologous lymphocytes inhibit haemopoiesis in long-term culture in patients with myelodysplastic syndrome. Exp Hematol 2002, 30:1405-1411.
65. Maciejewski J.P. Immune-mediated bone marrow failure syndromes of progenitor and stem cells: molecular analysis of cytotoxic T cell clones. Folia Histochem Cytobiol 2007, 45:5-14.
66. Sloand E.M., Mainwaring L., Fuhrer M., Ramkissoon S., Risitano A.M., Keyvanafar K., et al. Preferential suppression of trisomy 8 compared with normal hematopoietic cell growth by autologous lymphocytes in patients with trisomy 8 myelodysplastic syndrome. Blood 2005, 106:841-851.
67. Ruggiero G., Sica M., Luciano L., Savoia F., Cosentini E., Alfinito F., et al. A case of myelodysplastic syndrome associated with CD14(+)CD56(+) monocytosis, expansion of NK lymphocytes and defect of HLA-E expression. Leuk Res 2009, 33:181-185.
68. Epperson D.E., Nakamura R., Saunthararaja Y., Melenhorst J., Barrett A.J., Oligoclonal T cell expansion in myelodysplastic syndrome: evidence for an auto-immune process. Leuk Res 2001, 25:1075-1083.
69. Barrett A.J. Myelodysplastic syndrome: an example of misguided immune surveillance?. Leuk Res 2004, 28:1123-1124.
70. Sloand E.M., Rezvani K. The role of the immune system in myelodysplasia: implications for therapy. Semin Hematol 2008, 45:39-48.
71. Pellagatti A., Cazzola M., Giagounidis A.A., Malcovati L., Porta M.G., Killick S., et al. Gene expression profiles of CD34+ cells in myelodysplastic syndromes: involvement of interferon-stimulated genes and correlation to FAB subtype and karyotype. Blood 2006, 108:337-345.
72. Zeng W., Miyazato A., Chen G., Kajigaya S., Young N.S., Maciejewski J.P. Interferon-gamma-induced gene expression in CD34 cells: identification of pathologic cytokine-specific signature profiles. Blood 2006, 107:167-175.
73. Braun T., Carvalho G., Coquelle A., Vozenin M.C., Lepelley P., Hirsch F., et al. NF-kappaB constitutes a potential therapeutic target in high-risk myelodysplastic syndrome. Blood 2006, 107:1156-1165.
74. Parker J.E., Mufti G.J. Excessive apoptosis in low risk myelodysplastic syndromes (MDS). Leuk Lymphoma 2000, 40:1-24.
75. Carvalho G., Fabre C., Braun T., Grosjean J., Ades L., Agou F., et al. Inhibition of NEMO, the regulatory subunit of the IKK complex, induces apoptosis in high-risk myelodysplastic syndrome and acute myeloid leukemia. Oncogene 2007, 26:2299-2307.
76. Kordasti S.Y., Ingram W., Hayden J., Darling D., Barber L., Afzali B., et al. CD4+CD25+high Foxp3+ regulatory T cells in myelodysplastic syndrome (MDS). Blood 2007, 110:847-850.
77. Kotsianidis I., Bouchliou I., Nakou E., Spanoudakis E., Margaritis D., Christophoridou A.V., et al. Kinetics, function and bone marrow trafficking of CD4+CD25+FOXP3+ regulatory T cells in myelodysplastic syndromes (MDS). Leukemia 2009, 23:510-518.
78. Kiladjian J.J., Visentin G., Viey E., Chevret S., Eclache V., Stirnemann J., et al. Activation of cytotoxic T-cell receptor gammadelta T lymphocytes in response to specific stimulation in myelodysplastic syndromes. Haematologica 2008, 93:381-389.